Julian Symons
Vermogen: 148 524 $ op 31-07-2026
Vermogen: 148 524 $ op 31-07-2026
Julian A. Symons is Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. since 2018.
Formerly, Dr. Symons was Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Education includes a doctorate from York University and an undergraduate degree from the University of Central Lancashire.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 35.112 ( 0,65% ) | 148 524 $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2018 |
| Bedrijven | Functie | Einde |
|---|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Corporate Officer/Principal | 01-04-2018 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Central Lancashire
University of Central Lancashire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau